Potassium Chloride Extended-Release Capsules, USP 8 mEq and 10 mEq

Manufacturer
Par Pharmaceutical, Inc.
Effective date
2014-01-09
Label type
HUMAN PRESCRIPTION DRUG LABEL
Version
5
Source
legacy-cache
Hydrated at
2026-08-02 01:14:40

Label at a glance#

ProductPotassium Chloride Extended-Release
Active ingredientPOTASSIUM CHLORIDE
Label structure12 sections

Indications and uses

BECAUSE OF REPORTS OF INTESTINAL AND GASTRIC ULCERATION AND BLEEDING WITH CONTROLLED-RELEASE POTASSIUM CHLORIDE PREPARATIONS, THESE DRUGS SHOULD BE RESERVED FOR THOSE PATIENTS WHO CANNOT TOLERATE OR REFUSE TO TAKE LIQUID OR EFFERVESCENT POTASSIUM PREPARATIONS OR FOR PATIENTS IN WHOM THERE IS A PROBLEM OF COMPLIANCE WITH THESE PREPARATIONS. 1.For the treatment of patients with hypokalemia with or without metabolic ...

Dosage and administration

The usual dietary intake of potassium by the average adult is 50 to 100 mEq per day. Potassium depletion sufficient to cause hypokalemia usually requires the loss of 200 or more mEq of potassium from the total body store. Dosage must be adjusted to the individual needs of each patient. The dose for the prevention of hypokalemia is typically in the range of 20 mEq per day. Doses of 40 to100 mEq per day or more are ...

Label contents#

Full prescribing information#

SPL UNCLASSIFIED SECTION

Rx Only

DESCRIPTION

DESCRIPTION SECTION

Potassium Chloride Extended-Release Capsules, USP, are 8 mEq and 10 mEq are oral dosage forms of microencapsulated potassium chloride containing 600 and 750 mg, respectively, of potassium chloride, USP, equivalent to 8 and 10 mEq of potassium.

Dispersibility of potassium chloride (KCl) is accomplished by microencapsulation and a dispersing agent. The resultant flow characteristics of the KCl microcapsules and the controlled release of K+ ions by the microcapsular membrane are intended to avoid the possibility that excessive amounts of KCl can be localized at any point on the mucosa of the gastrointestinal tract.

Each crystal of KCl is microencapsulated by a process with an insoluble polymeric coating which functions as a semi-permeable membrane; it allows for the controlled release of potassium and chloride ions over an eight- to ten-hour period. Fluids pass through the membrane and gradually dissolve the potassium chloride within the micro-capsules. The resulting potassium chloride solution slowly diffuses outward through the membrane. Potassium chloride extended-release capsules are electrolyte replenishers. The chemical name of the active ingredient is potassium chloride and the structural formula is KCl. Potassium chloride, occurs as a white, granular powder or as colorless crystals. It is odorless and has a saline taste. Its solutions are neutral to litmus. It is freely soluble in water and insoluble in alcohol.

The inactive ingredients are, ethylcellulose, gelatin, sodium lauryl sulfate, FD&C Blue #1, FD&C Red #40, titanium oxide, triacetin, shellac, iron oxide black, isopropyl alcohol, n-butyl alcohol, propylene glycol, ammonium hydroxide, FD&C Blue #2, FD&C Red #40, FD&C Blue #1 and D&C Yellow #10.

CLINICAL PHARMACOLOGY

CLINICAL PHARMACOLOGY SECTION

Potassium ion is the principal intracellular cation of most body tissues. Potassium ions participate in a number of essential physiological processes, including the maintenance of intracellular tonicity, the transmission of nerve impulses, the contraction of cardiac, skeletal, and smooth muscle, and the maintenance of normal renal function.

The intracellular concentration of potassium is approximately 150 to 160 mEq per liter. The normal adult plasma concentration is 3.5 to 5 mEq per liter. An active ion transport system maintains this gradient across the plasma membrane.

Potassium is a normal dietary constituent and under steady-state conditions the amount of potassium absorbed from the gastrointestinal tract is equal to the amount excreted in the urine. The usual dietary intake of potassium is 50 to 100 mEq per day.

Potassium depletion will occur whenever the rate of potassium loss through renal excretion and/or loss from the gastrointestinal tract exceeds the rate of potassium intake. Such depletion usually develops slowly as a consequence of therapy with diuretics, primary or secondary hyperaldosteronisms, diabetic ketoacidosis, or inadequate replacement of potassium in patients on prolonged parenteral nutrition.

Depletion can develop rapidly with severe diarrhea, especially if associated with vomiting. Potassium depletion due to these causes is usually accompanied by a concomitant loss of chloride and is manifested by hypokalemia and metabolic alkalosis. Potassium depletion may produce weakness, fatigue, disturbances of cardiac rhythm (primarily ectopic beats), prominent U-waves in the electrocardiogram, and in advanced cases, flaccid paralysis and/or impaired ability to concentrate urine.

If potassium depletion associated with metabolic alkalosis cannot be managed by correcting the fundamental cause of the deficiency, e.g., where the patient requires long-term diuretic therapy, supplemental potassium in the form of high potassium food or potassium chloride may be able to restore normal potassium levels.

In rare circumstances (e.g., patients with renal tubular acidosis) potassium depletion may be associated with metabolic acidosis and hyperchloremia. In such patients potassium replacement should be accomplished with potassium salts other than the chloride, such as potassium bicarbonate, potassium citrate, potassium acetate, or potassium gluconate.

INDICATIONS AND USAGE

INDICATIONS & USAGE SECTION

BECAUSE OF REPORTS OF INTESTINAL AND GASTRIC ULCERATION AND BLEEDING WITH CONTROLLED-RELEASE POTASSIUM CHLORIDE PREPARATIONS, THESE DRUGS SHOULD BE RESERVED FOR THOSE PATIENTS WHO CANNOT TOLERATE OR REFUSE TO TAKE LIQUID OR EFFERVESCENT POTASSIUM PREPARATIONS OR FOR PATIENTS IN WHOM THERE IS A PROBLEM OF COMPLIANCE WITH THESE PREPARATIONS.

  • 1.For the treatment of patients with hypokalemia with or without metabolic alkalosis, in digitalis intoxications, and in patients with hypokalemic familial periodic paralysis. If hypokalemia is the result of diuretic therapy, consideration should be given to the use of a lower dose of diuretic, which may be sufficient without leading to hypokalemia.
  • 2.For the prevention of hypokalemia in patients who would be at particular risk if hypokalemia were to develop e.g., digitalized patients or patients with significant cardiac arrhythmias, hepatic cirrhosis with ascites, states of aldosterone excess with normal renal function, potassium-losing nephropathy, and certain diarrheal states.

The use of potassium salts in patients receiving diuretics for uncomplicated essential hypertension is often unnecessary when such patients have a normal dietary pattern and when low doses of the diuretic are used. Serum potassium should be checked periodically, however, and if hypokalemia occurs, dietary supplementation with potassium-containing foods may be adequate to control milder cases. In more severe cases, and if dose adjustment of the diuretic is ineffective or unwarranted, supplementation with potassium salts may be indicated.

CONTRAINDICATIONS

CONTRAINDICATIONS SECTION

Potassium supplements are contraindicated in patients with hyperkalemia since a further increase in serum potassium concentration in such patients can produce cardiac arrest. Hyperkalemia may complicate any of the following conditions: chronic renal failure, systemic acidosis such as diabetic acidosis, acute dehydration, extensive tissue breakdown as in severe burns, adrenal insufficiency, or the administration of a potassium-sparing diuretic (e.g., spironolactone, triamterene, amiloride) (see OVERDOSAGE).

Controlled-release formulations of potassium chloride have produced esophageal ulceration in certain cardiac patients with esophageal compression due to an enlarged left atrium. Potassium supplementation, when indicated in such patients, should be given as a liquid preparation.

All solid oral dosage forms of potassium chloride are contraindicated in any patient in whom there is structural, pathological (e.g., diabetic gastroparesis) or pharmacologic (use of anticholinergic agents or other agents with anticholinergic properties at sufficient doses to exert anticholinergic effects) cause for arrest or delay in capsule passage through the gastrointestinal tract.

WARNINGS

WARNINGS SECTION

Hyperkalemia (see OVERDOSAGE)

SPL UNCLASSIFIED SECTION

In patients with impaired mechanisms for excreting potassium, the administration of potassium salts can produce hyperkalemia and cardiac arrest. This occurs most commonly in patients given potassium by the intravenous route but may also occur in patients given potassium orally. Potentially fatal hyperkalemia can develop rapidly and be asymptomatic. The use of potassium salts in patients with chronic renal disease, or any other condition which impairs potassium excretion, requires particularly careful monitoring of the serum potassium concentration and appropriate dosage adjustments.

Interaction with Potassium-Sparing Diuretics

SPL UNCLASSIFIED SECTION

Hypokalemia should not be treated by the concomitant administration of potassium salts and a potassium-sparing diuretic (e.g., spironolactone, triamterene or amiloride) since the simultaneous administration of these agents can produce severe hyperkalemia.

Interaction with Angiotensin Converting Enzyme Inhibitors

SPL UNCLASSIFIED SECTION

Angiotensin converting enzyme (ACE) inhibitors (e.g., captopril, enalapril) will produce some potassium retention by inhibiting aldosterone production. Potassium supplements should be given to patients receiving ACE inhibitors only with close monitoring.

Gastrointestinal Lesions

SPL UNCLASSIFIED SECTION

Solid oral dosage forms of potassium chloride can produce ulcerative and/or stenotic lesions of the gastrointestinal tract. Based on spontaneous adverse reaction reports, enteric coated preparations of potassium chloride are associated with an increased frequency of small bowel lesions (40 to 50 per 100,000 patient years) compared to sustained-release wax matrix formulations (less than one per 100,000 patient years). Because of the lack of extensive marketing experience with microencapsulated products, a comparison between such products and wax matrix or enteric-coated products is not available. Potassium chloride extended-release capsules, are microencapsulated capsules formulated to provide a controlled rate of release of microencapsulated potassium chloride and thus to minimize the possibility of high local concentration of potassium near the gastrointestinal wall.

Prospective trials have been conducted in normal human volunteers in which the upper gastrointestinal tract was evaluated by endoscopic inspection before and after one week of solid oral potassium chloride therapy. The ability of this model to predict events occurring in usual clinical practice is unknown. Trials which approximated usual clinical practice did not reveal any clear differences between the wax matrix and microencapsulated dosage forms. In contrast, there was a higher incidence of gastric and duodenal lesions in subjects receiving a high dose of a wax matrix controlled-release formulation under conditions which did not resemble usual or recommended clinical practice (i.e., 96 mEq per day in divided doses of potassium chloride administered to fasted patients, in the presence of an anticholinergic drug to delay gastric emptying). The upper gastrointestinal lesions observed by endoscopy were asymptomatic and were not accompanied by evidence of bleeding (hemoccult testing). The relevance of these findings to the usual conditions (i.e., non-fasting, no anticholinergic agent, smaller doses) under which controlled-release potassium chloride products are used is uncertain; epidemiologic studies have not identified an elevated risk, compared to microencapsulated products, for upper gastrointestinal lesions in patients receiving wax matrix formulations. Potassium chloride extended-release capsules should be discontinued immediately and the possibility of ulceration, obstruction or perforation considered if severe vomiting, abdominal pain, distention, or gastrointestinal bleeding occur.

Metabolic Acidosis

SPL UNCLASSIFIED SECTION

Hypokalemia in patients with metabolic acidosis should be treated with an alkalinizing potassium salt such as potassium bicarbonate, potassium citrate, potassium acetate, or potassium gluconate.

PRECAUTIONS

PRECAUTIONS SECTION

General

GENERAL PRECAUTIONS SECTION

The diagnosis of potassium depletion is ordinarily made by demonstrating hypokalemia in a patient with a clinical history suggesting some cause for potassium depletion. In interpreting the serum potassium level, the physician should bear in mind that acute alkalosis per se can produce hypokalemia in the absence of a deficit in total body potassium, while acute acidosis per se can increase the serum potassium concentration into the normal range even in the presence of a reduced total body potassium. The treatment of potassium depletion, particularly in the presence of cardiac disease, renal disease, or acidosis, requires careful attention to acid-base balance and appropriate monitoring of serum electrolytes, the electrocardiogram, and the clinical status of the patient.

Information for Patients

INFORMATION FOR PATIENTS SECTION

Physicians should consider reminding the patient of the following: To take each dose with meals and with a full glass of water or other suitable liquid. To take each dose without crushing, chewing, or sucking the capsules. To take this medicine following the frequency and amount prescribed by the physician. This is especially important if the patient is also taking diuretics and/or digitalis preparations. To check with the physician if there is trouble swallowing capsules or if the capsules seem to stick in the throat.

To check with the physician at once if tarry stools or other evidence of gastrointestinal bleeding is noticed.

Laboratory Tests

LABORATORY TESTS SECTION

Regular serum potassium determinations are recommended, especially in patients with renal insufficiency or diabetic nephropathy. When blood is drawn for analysis of plasma potassium it is important to recognize that artifactual elevations can occur after improper venipuncture technique or as a result of in vitro hemolysis of the sample.

Drug Interactions

DRUG INTERACTIONS SECTION

Potassium-sparing diuretics, angiotensin converting enzyme inhibitors: (see WARNINGS).

Carcinogenesis, Mutagenesis, Impairment of Fertility

CARCINOGENESIS & MUTAGENESIS & IMPAIRMENT OF FERTILITY SECTION

Carcinogenicity, mutagenicity and fertility studies in animals have not been performed. Potassium is a normal dietary constituent.

Pregnancy: Teratogenic Effects: Category C

PREGNANCY SECTION

Animal reproduction studies have not been conducted with potassium chloride extended-release capsules. It is unlikely that potassium supplementation that does not lead to hyperkalemia would have an adverse effect on the fetus or would affect reproductive capacity.

Nursing Mothers

NURSING MOTHERS SECTION

The normal potassium ion content of human milk is about 13 mEq per liter. Since oral potassium becomes part of the body potassium pool, so long as body potassium is not excessive, the contribution of potassium chloride supplementation should have little or no effect on the level in human milk.

Pediatric Use

PEDIATRIC USE SECTION

Safety and effectiveness in pediatric patients have not been established.

Geriatric Use

GERIATRIC USE SECTION

Clinical studies of potassium chloride extended-release capsules did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. Other reported clinical experience has not identified differences in responses between the elderly and younger patients. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.

This drug is known to be substantially excreted by the kidney, and the risk of toxic reactions to this drug may be greater in patients with impaired renal function. Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection, and it may be useful to monitor renal function.

ADVERSE REACTIONS

ADVERSE REACTIONS SECTION

One of the most severe adverse effects is hyperkalemia (see CONTRAINDICATIONS, WARNINGS, and OVERDOSAGE). Gastrointestinal bleeding and ulceration have been reported in patients treated with potassium chloride extended-release capsules, (see CONTRAINDICATIONS and WARNINGS). In addition to gastrointestinal bleeding and ulceration, perforation and obstruction have been reported in patients treated with other solid KCl dosage forms, and may occur with potassium chloride extended-release capsules, USP, 8 mEq and 100 mEq. The most common adverse reactions to the oral potassium salts are nausea, vomiting, flatulence, abdominal discomfort, and diarrhea. These symptoms are due to irritation of the gastrointestinal tract and are best managed by taking the dose with meals, or reducing the amount taken at one time. Skin rash has been reported rarely with potassium preparations.

To report SUSPECTED ADVERSE REACTIONS, contact Par Pharmaceutical, Inc. at 1-800-828-9393 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

OVERDOSAGE

OVERDOSAGE SECTION

The administration of oral potassium salts to persons with normal excretory mechanisms for potassium rarely causes serious hyperkalemia. However, if excretory mechanisms are impaired or if potassium is administered too rapidly intravenously, potentially fatal hyperkalemia can result (see CONTRAINDICATIONS and WARNINGS). It is important to recognize that hyperkalemia is usually asymptomatic and may be manifested only by an increased serum potassium concentration (6.5 to 8.0 mEq/L) and characteristic electrocardiographic changes (peaking of T-waves, loss of P-waves, depression of ST segment, and prolongation of the QT interval). Late manifestations include muscle paralysis and cardiovascular collapse from cardiac arrest (9 to 12 mEq/L).

Treatment measures for hyperkalemia include the following: (1) elimination of foods and medications containing potassium and of any agents with potassium-sparing properties; (2) intravenous administration of 300 to 500 mL/hr of 10% dextrose solution containing 10 to 20 units of crystalline insulin per 1,000 mL; (3) correction of acidosis, if present, with intravenous sodium bicarbonate; (4) use of exchange resins, hemodialysis, or peritoneal dialysis. In treating hyperkalemia, it should be recalled that in patients who have been stabilized on digitalis, too rapid a lowering of the serum potassium concentration can produce digitalis toxicity. The extended release feature means that absorption and toxic effects may be delayed for hours. Consider standard measures to remove any unabsorbed drug.

DOSAGE AND ADMINISTRATION

DOSAGE & ADMINISTRATION SECTION

The usual dietary intake of potassium by the average adult is 50 to 100 mEq per day. Potassium depletion sufficient to cause hypokalemia usually requires the loss of 200 or more mEq of potassium from the total body store.

Dosage must be adjusted to the individual needs of each patient. The dose for the prevention of hypokalemia is typically in the range of 20 mEq per day. Doses of 40 to100 mEq per day or more are used for the treatment of potassium depletion. Dosage should be divided if more than 20 mEq per day is given such that no more than 20 mEq is given in a single dose. Because of the potential for gastric irritation (see WARNINGS), potassium chloride extended-release capsules, should be taken with meals and with a full glass of water or other liquid.

Patients who have difficulty swallowing capsules may sprinkle the contents of the capsule onto a spoonful of soft food. The soft food, such as applesauce or pudding, should be swallowed immediately without chewing and followed with a glass of cool water or juice to ensure complete swallowing of the microcapsules. The food used should not be hot and should be soft enough to be swallowed without chewing. Any microcapsule/food mixture should be used immediately and not stored for future use.

HOW SUPPLIED

HOW SUPPLIED SECTION

Potassium Chloride Extended-Release Capsules, USP, 8 mEq (600 mg) in a hard gelatin capsule with white opaque cap imprinted with “par” and white opaque body imprinted with “C219” in black ink containing white to off white spherical shaped coated pellets.

Bottles of 100 (NDC 10370-219-01)
Bottles of 500 (NDC 10370-219-05)

Potassium Chloride Extended-Release Capsules, USP, 10 mEq (750 mg) in a hard gelatin capsule with dark blue opaque cap imprinted with “par” and dark blue opaque body imprinted with “C220” in black ink containing white to off white spherical coated pellets.

Bottles of 100 (NDC 10370-220-01)
Bottles of 500 (NDC 10370-220-05)

Storage

SPL UNCLASSIFIED SECTION

Potassium chloride extended-release capsules are store at controlled room temperature, 20º to 25ºC (68º to 77ºF).
[see USP Controlled Room Temperature].

Dispense in tight, light-resistant container as defined in the USP.

Manufactured by:

Par Pharmaceutical Companies, Inc.
Spring Valley, NY 10977

I04/13

PACKAGE/LABEL PRINCIPAL DISPLAY PANEL

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL

NDC 10370-219-01
Potassium Chloride
Extended-Release Capsules, USP
8 mEq
100-count and 500-count
Rx Only

Potassium Chloride 8 mEq
Potassium Chloride 8 mEq

NDC 10370-220-01
Potassium Chloride
Extended-Release Capsules, USP
10 mEq
100-count and 500-count
Rx Only

Potassium Chloride 10 mEq
Potassium Chloride 10 mEq

DailyMed Billing Units#

Package NDC, Billing unit, Product NDC table
Package NDCBilling unitProduct NDCDailyMed indexing SPLSPL versionEffective
10370-219-01EA - Each10370-2199c12a1f2-4921-4501-a1b4-2f74125187b012014-04-03
10370-219-05EA - Each10370-219e4e55be6-66c7-4866-81f8-752cb590a71412014-04-03
10370-220-01EA - Each10370-220b1336f1b-1af2-4638-afdf-90fdb41c921812014-04-03
10370-220-05EA - Each10370-2208a5f15d1-3da1-4058-98c1-1c4f14cfda5a12014-04-03

DailyMed Socrata Ingredients#

Ingredient, Type, UNII table
IngredientTypeUNIISPL versionUploaded
POTASSIUM CHLORIDEACTIVE INGREDIENT660YQ98I103
POTASSIUM CATIONACTIVE MOIETY295O53K1523
AMMONIAINACTIVE INGREDIENT5138Q19F1X3
BUTYL ALCOHOLINACTIVE INGREDIENT8PJ61P6TS33
D&C YELLOW NO. 10INACTIVE INGREDIENT35SW5USQ3G3
ETHYLCELLULOSESINACTIVE INGREDIENT7Z8S9VYZ4B3
FD&C BLUE NO. 1INACTIVE INGREDIENTH3R47K3TBD3
FD&C BLUE NO. 2INACTIVE INGREDIENTL06K8R7DQK3
FD&C RED NO. 40INACTIVE INGREDIENTWZB9127XOA3
FERROSOFERRIC OXIDEINACTIVE INGREDIENTXM0M87F3573
GELATININACTIVE INGREDIENT2G86QN327L3
ISOPROPYL ALCOHOLINACTIVE INGREDIENTND2M4163023
PROPYLENE GLYCOLINACTIVE INGREDIENT6DC9Q167V33
SHELLACINACTIVE INGREDIENT46N107B71O3
SODIUM LAURYL SULFATEINACTIVE INGREDIENT368GB5141J3
TITANIUM DIOXIDEINACTIVE INGREDIENT15FIX9V2JP3
TRIACETININACTIVE INGREDIENTXHX3C3X6733

Products#

Every source-derived product name is available through these pages.

DailyMed product names page 1 of 1 · 18 matching rows.

NDC Codes#

Product NDC, Package NDC table
Product NDCPackage NDC
10370-21910370-219-01, 10370-219-05
10370-22010370-220-01, 10370-220-05

Ingredients#

Every source-derived ingredient row is available through these pages.

DailyMed ingredient rows page 1 of 1 · 32 matching rows.

Source Document#

Source XML

Inactive ingredient matches#

Inactive Ingredient Database values describe FDA-listed use contexts. The match method and ambiguity count are shown because ingredient names, routes, and dosage forms are not always unique. Browse recovered IID releases and source provenance.

Inactive ingredient links page 1 of 7 · 400 matching rows.

DailyMed ingredient, IID ingredient, UNII table
DailyMed ingredientIID ingredientUNIIDosage form / routePotencyMaximum daily exposureMatch
SHELLACSHELLAC46N107B71OCAPSULE, EXTENDED RELEASE / ORAL75.01 mgExact identifier — unii candidate
13 equally ranked IID candidates
ETHYLCELLULOSESETHYLCELLULOSE7Z8S9VYZ4BCAPSULE / ORAL12.32 mgExact identifier — unii candidate
14 equally ranked IID candidates
BUTYL ALCOHOLBUTYL ALCOHOL8PJ61P6TS3CAPSULE / ORAL0.02 mgExact identifier — unii candidate
10 equally ranked IID candidates
SODIUM LAURYL SULFATESODIUM LAURYL SULFATE368GB5141JPASTE, DENTIFRICE / DENTAL1.4 %w/wExact identifier — unii candidate
42 equally ranked IID candidates
FD&C BLUE NO. 1FD&C BLUE NO. 1H3R47K3TBDDOUCHE / VAGINALNAExact identifier — unii candidate
37 equally ranked IID candidates
FERROSOFERRIC OXIDEFERROSOFERRIC OXIDEXM0M87F357TABLET, FILM COATED / ORAL0.2 mgExact identifier — unii candidate
10 equally ranked IID candidates
PROPYLENE GLYCOLPROPYLENE GLYCOL6DC9Q167V3SPRAY, METERED / NASAL240 mgExact identifier — unii candidate
81 equally ranked IID candidates
TRIACETINTRIACETINXHX3C3X673SYSTEM / TRANSDERMAL22.1 mgExact identifier — unii candidate
14 equally ranked IID candidates
ISOPROPYL ALCOHOLISOPROPYL ALCOHOLND2M416302SWAB / TOPICAL43.9 %w/wExact identifier — unii candidate
11 equally ranked IID candidates
SODIUM LAURYL SULFATESODIUM LAURYL SULFATE368GB5141JSHAMPOO / TOPICAL65 %w/wExact identifier — unii candidate
42 equally ranked IID candidates
PROPYLENE GLYCOLPROPYLENE GLYCOL6DC9Q167V3SPRAY / SUBLINGUAL36 mgExact identifier — unii candidate
81 equally ranked IID candidates
SHELLACSHELLAC46N107B71OTABLET, EXTENDED RELEASE / ORAL213.24 mgExact identifier — unii candidate
13 equally ranked IID candidates
FD&C RED NO. 40FD&C RED NO. 40WZB9127XOATABLET, EXTENDED RELEASE / ORAL2.22 mgExact identifier — unii candidate
28 equally ranked IID candidates
ETHYLCELLULOSESETHYLCELLULOSE7Z8S9VYZ4BPOWDER / ORAL2090 mgExact identifier — unii candidate
14 equally ranked IID candidates
BUTYL ALCOHOLBUTYL ALCOHOL8PJ61P6TS3TABLET, DELAYED RELEASE / ORAL0.05 mgExact identifier — unii candidate
10 equally ranked IID candidates
SODIUM LAURYL SULFATESODIUM LAURYL SULFATE368GB5141JINSERT / VAGINAL15 mgExact identifier — unii candidate
42 equally ranked IID candidates
SODIUM LAURYL SULFATESODIUM LAURYL SULFATE368GB5141JCAPSULE, DELAYED RELEASE PELLETS / ORAL99 mgExact identifier — unii candidate
42 equally ranked IID candidates
PROPYLENE GLYCOLPROPYLENE GLYCOL6DC9Q167V3INJECTION / INTRAVENOUS16624 mgExact identifier — unii candidate
81 equally ranked IID candidates
D&C YELLOW NO. 10D&C YELLOW NO. 1035SW5USQ3GCAPSULE, DELAYED RELEASE / ORAL1 mgExact identifier — unii candidate
31 equally ranked IID candidates
TITANIUM DIOXIDETITANIUM DIOXIDE15FIX9V2JPSOAP / TOPICAL1 %w/wExact identifier — unii candidate
40 equally ranked IID candidates
TITANIUM DIOXIDETITANIUM DIOXIDE15FIX9V2JPCAPSULE, LIQUID FILLED / ORAL12 mgExact identifier — unii candidate
40 equally ranked IID candidates
D&C YELLOW NO. 10D&C YELLOW NO. 1035SW5USQ3GLOTION / TOPICALNAExact identifier — unii candidate
31 equally ranked IID candidates
FD&C RED NO. 40FD&C RED NO. 40WZB9127XOASYRUP / ORAL3 mgExact identifier — unii candidate
28 equally ranked IID candidates
SODIUM LAURYL SULFATESODIUM LAURYL SULFATE368GB5141JLOTION / TOPICAL111 mgExact identifier — unii candidate
42 equally ranked IID candidates
SODIUM LAURYL SULFATESODIUM LAURYL SULFATE368GB5141JCAPSULE, EXTENDED RELEASE / ORAL166 mgExact identifier — unii candidate
42 equally ranked IID candidates
GELATINGELATIN2G86QN327LCAPSULE, COATED / ORAL288 mgExact identifier — unii candidate
44 equally ranked IID candidates
FD&C BLUE NO. 1FD&C BLUE NO. 1H3R47K3TBDTABLET, COATED / ORAL0.52 mgExact identifier — unii candidate
37 equally ranked IID candidates
TRIACETINTRIACETINXHX3C3X673CAPSULE, DELAYED RELEASE / ORAL5.1 mgExact identifier — unii candidate
14 equally ranked IID candidates
TITANIUM DIOXIDETITANIUM DIOXIDE15FIX9V2JPINSERT, EXTENDED RELEASE / OPHTHALMIC0.4 mgExact identifier — unii candidate
40 equally ranked IID candidates
D&C YELLOW NO. 10D&C YELLOW NO. 1035SW5USQ3GSHAMPOO / TOPICALNAExact identifier — unii candidate
31 equally ranked IID candidates
ETHYLCELLULOSESETHYLCELLULOSE7Z8S9VYZ4BPOWDER, FOR SUSPENSION / ORALNAExact identifier — unii candidate
14 equally ranked IID candidates
FD&C BLUE NO. 1FD&C BLUE NO. 1H3R47K3TBDSOAP / TOPICAL0.01 %w/wExact identifier — unii candidate
37 equally ranked IID candidates
TITANIUM DIOXIDETITANIUM DIOXIDE15FIX9V2JPGRANULE, FOR SUSPENSION / ORAL143 mgExact identifier — unii candidate
40 equally ranked IID candidates
SODIUM LAURYL SULFATESODIUM LAURYL SULFATE368GB5141JOINTMENT / TOPICAL14 mgExact identifier — unii candidate
42 equally ranked IID candidates
PROPYLENE GLYCOLPROPYLENE GLYCOL6DC9Q167V3SUSPENSION, EXTENDED RELEASE / ORAL1000 mgExact identifier — unii candidate
81 equally ranked IID candidates
PROPYLENE GLYCOLPROPYLENE GLYCOL6DC9Q167V3TABLET, DELAYED RELEASE / ORAL36 mgExact identifier — unii candidate
81 equally ranked IID candidates
AMMONIAAMMONIA SOLUTION5138Q19F1XINJECTION / SUBCUTANEOUSADJ PHExact identifier — unii candidate
14 equally ranked IID candidates
D&C YELLOW NO. 10D&C YELLOW NO. 1035SW5USQ3GGEL / DENTALNAExact identifier — unii candidate
31 equally ranked IID candidates
PROPYLENE GLYCOLPROPYLENE GLYCOL6DC9Q167V3SOLUTION / OPHTHALMIC1 %w/vExact identifier — unii candidate
81 equally ranked IID candidates
AMMONIAAMMONIA SOLUTION5138Q19F1XTABLET, EXTENDED RELEASE / ORAL6 mgExact identifier — unii candidate
14 equally ranked IID candidates
PROPYLENE GLYCOLPROPYLENE GLYCOL6DC9Q167V3CREAM / TOPICAL76000 mgExact identifier — unii candidate
81 equally ranked IID candidates
GELATINGELATIN2G86QN327LCAPSULE, LIQUID FILLED / ORAL1042 mgExact identifier — unii candidate
44 equally ranked IID candidates
TITANIUM DIOXIDETITANIUM DIOXIDE15FIX9V2JPTABLET / ORAL232 mgExact identifier — unii candidate
40 equally ranked IID candidates
FD&C RED NO. 40FD&C RED NO. 40WZB9127XOASUSPENSION/ DROPS / ORAL1 mgExact identifier — unii candidate
28 equally ranked IID candidates
TITANIUM DIOXIDETITANIUM DIOXIDE15FIX9V2JPTABLET, FILM COATED, EXTENDED RELEASE / ORAL11 mgExact identifier — unii candidate
40 equally ranked IID candidates
PROPYLENE GLYCOLPROPYLENE GLYCOL6DC9Q167V3OINTMENT / RECTAL27 mgExact identifier — unii candidate
81 equally ranked IID candidates
TITANIUM DIOXIDETITANIUM DIOXIDE15FIX9V2JPPASTE / DENTAL0.5 %w/wExact identifier — unii candidate
40 equally ranked IID candidates
PROPYLENE GLYCOLPROPYLENE GLYCOL6DC9Q167V3TABLET, EXTENDED RELEASE / ORAL9 mgExact identifier — unii candidate
81 equally ranked IID candidates
PROPYLENE GLYCOLPROPYLENE GLYCOL6DC9Q167V3SPRAY / NASAL5 mgExact identifier — unii candidate
81 equally ranked IID candidates
GELATINGELATIN2G86QN327LTABLET / ORAL46 mgExact identifier — unii candidate
44 equally ranked IID candidates
BUTYL ALCOHOLBUTYL ALCOHOL8PJ61P6TS3TABLET / ORAL0.01 mgExact identifier — unii candidate
10 equally ranked IID candidates
TITANIUM DIOXIDETITANIUM DIOXIDE15FIX9V2JPSYSTEM / TOPICAL420 mgExact identifier — unii candidate
40 equally ranked IID candidates
BUTYL ALCOHOLBUTYL ALCOHOL8PJ61P6TS3CAPSULE, EXTENDED RELEASE / ORAL0.01 mgExact identifier — unii candidate
10 equally ranked IID candidates
SODIUM LAURYL SULFATESODIUM LAURYL SULFATE368GB5141JSHAMPOO, SUSPENSION / TOPICAL40 %w/vExact identifier — unii candidate
42 equally ranked IID candidates
PROPYLENE GLYCOLPROPYLENE GLYCOL6DC9Q167V3SOLUTION / RESPIRATORY (INHALATION)25 %w/wExact identifier — unii candidate
81 equally ranked IID candidates
PROPYLENE GLYCOLPROPYLENE GLYCOL6DC9Q167V3GEL / TOPICAL4522 mgExact identifier — unii candidate
81 equally ranked IID candidates
FD&C RED NO. 40FD&C RED NO. 40WZB9127XOAPOWDER, FOR SUSPENSION / ORAL3 mgExact identifier — unii candidate
28 equally ranked IID candidates
FD&C RED NO. 40FD&C RED NO. 40WZB9127XOACAPSULE, COATED PELLETS / ORALNAExact identifier — unii candidate
28 equally ranked IID candidates
SODIUM LAURYL SULFATESODIUM LAURYL SULFATE368GB5141JTABLET, ORALLY DISINTEGRATING / ORAL16 mgExact identifier — unii candidate
42 equally ranked IID candidates
TITANIUM DIOXIDETITANIUM DIOXIDE15FIX9V2JPTABLET, DELAYED RELEASE / ORAL66 mgExact identifier — unii candidate
40 equally ranked IID candidates

Orange Book application contexts#

All distinct exact application/product contexts derived from this label’s complete NDC list are paginated below.

Orange Book application contexts page 1 of 1 · 1 matching rows.

Source provenance: Browse the complete Orange Book source catalog · source snapshot 45.

Orange Book products#

Current product rows page 1 of 1 · 2 matching rows.

Application-product, Trade name, Ingredient table
Application-productTrade nameIngredientStrengthDosage form / routeTE codesRLD / RSApproval date
A202886-001POTASSIUM CHLORIDEPOTASSIUM CHLORIDE8MEQCAPSULE, EXTENDED RELEASE / ORAL2013-12-26
A202886-002POTASSIUM CHLORIDEPOTASSIUM CHLORIDE10MEQCAPSULE, EXTENDED RELEASE / ORAL2013-12-26

Observed Orange Book product history#

Observed FDA ZIP history: Each table is queried independently by exact application/product key from successfully parsed Orange Book snapshots. Capture times identify archived source observations; absence or a change between snapshots is not inferred. FDA publication files that were not recoverable as structured ZIP data are not represented as states.

Product history page 1 of 3 · 90 observed states.

Captured, Edition, Application-product table
CapturedEditionApplication-productTrade nameStrengthDosage form / routeProduct TE source textRLD / RSApproval dateSource SHA-256
2026-11-14 07:37:172026-10A202886-001POTASSIUM CHLORIDE8MEQCAPSULE, EXTENDED RELEASE / ORAL2013-12-26d4dbc9d85df4…
2026-11-14 07:37:172026-10A202886-002POTASSIUM CHLORIDE10MEQCAPSULE, EXTENDED RELEASE / ORAL2013-12-26d4dbc9d85df4…
2026-10-15 13:18:302026-09A202886-001POTASSIUM CHLORIDE8MEQCAPSULE, EXTENDED RELEASE / ORAL2013-12-26c2088c7a36db…
2026-10-15 13:18:302026-09A202886-002POTASSIUM CHLORIDE10MEQCAPSULE, EXTENDED RELEASE / ORAL2013-12-26c2088c7a36db…
2026-09-14 22:38:342026-08A202886-001POTASSIUM CHLORIDE8MEQCAPSULE, EXTENDED RELEASE / ORAL2013-12-2684e616aacf4f…
2026-09-14 22:38:342026-08A202886-002POTASSIUM CHLORIDE10MEQCAPSULE, EXTENDED RELEASE / ORAL2013-12-2684e616aacf4f…
2026-08-18 06:07:402026-07A202886-001POTASSIUM CHLORIDE8MEQCAPSULE, EXTENDED RELEASE / ORAL2013-12-26caaa826d4ba7…
2026-08-18 06:07:402026-07A202886-002POTASSIUM CHLORIDE10MEQCAPSULE, EXTENDED RELEASE / ORAL2013-12-26caaa826d4ba7…
2026-02-19 14:30 UTC2026-02A202886-001POTASSIUM CHLORIDE8MEQCAPSULE, EXTENDED RELEASE / ORAL2013-12-26011fe1cb6892…
2026-02-19 14:30 UTC2026-02A202886-002POTASSIUM CHLORIDE10MEQCAPSULE, EXTENDED RELEASE / ORAL2013-12-26011fe1cb6892…
2025-12-14 10:44 UTC · 2 captures of this ZIP2025-12A202886-001POTASSIUM CHLORIDE8MEQCAPSULE, EXTENDED RELEASE / ORAL2013-12-2631067a03dcf5…
2025-12-14 10:44 UTC · 2 captures of this ZIP2025-12A202886-002POTASSIUM CHLORIDE10MEQCAPSULE, EXTENDED RELEASE / ORAL2013-12-2631067a03dcf5…
2025-08-23 18:47 UTC2025-08A202886-001POTASSIUM CHLORIDE8MEQCAPSULE, EXTENDED RELEASE / ORAL2013-12-266a471c1ec25d…
2025-08-23 18:47 UTC2025-08A202886-002POTASSIUM CHLORIDE10MEQCAPSULE, EXTENDED RELEASE / ORAL2013-12-266a471c1ec25d…
2025-03-22 03:13 UTC · 3 captures of this ZIP2025-03A202886-001POTASSIUM CHLORIDE8MEQCAPSULE, EXTENDED RELEASE / ORAL2013-12-26fd3edfee7708…
2025-03-22 03:13 UTC · 3 captures of this ZIP2025-03A202886-002POTASSIUM CHLORIDE10MEQCAPSULE, EXTENDED RELEASE / ORAL2013-12-26fd3edfee7708…
2025-02-26 10:13 UTC · 3 captures of this ZIP2025-02A202886-001POTASSIUM CHLORIDE8MEQCAPSULE, EXTENDED RELEASE / ORAL2013-12-26b8a1b40f171c…
2025-02-26 10:13 UTC · 3 captures of this ZIP2025-02A202886-002POTASSIUM CHLORIDE10MEQCAPSULE, EXTENDED RELEASE / ORAL2013-12-26b8a1b40f171c…
2025-01-19 17:59 UTC · 7 captures of this ZIP2025-01A202886-001POTASSIUM CHLORIDE8MEQCAPSULE, EXTENDED RELEASE / ORAL2013-12-2603ed91905a0d…
2025-01-19 17:59 UTC · 7 captures of this ZIP2025-01A202886-002POTASSIUM CHLORIDE10MEQCAPSULE, EXTENDED RELEASE / ORAL2013-12-2603ed91905a0d…
2024-12-13 21:23 UTC · 2 captures of this ZIP2024-12A202886-001POTASSIUM CHLORIDE8MEQCAPSULE, EXTENDED RELEASE / ORAL2013-12-262680178bc6a6…
2024-12-13 21:23 UTC · 2 captures of this ZIP2024-12A202886-002POTASSIUM CHLORIDE10MEQCAPSULE, EXTENDED RELEASE / ORAL2013-12-262680178bc6a6…
2024-09-14 05:58 UTC · 2 captures of this ZIP2024-09A202886-001POTASSIUM CHLORIDE8MEQCAPSULE, EXTENDED RELEASE / ORAL2013-12-265bbf6a4d5a75…
2024-09-14 05:58 UTC · 2 captures of this ZIP2024-09A202886-002POTASSIUM CHLORIDE10MEQCAPSULE, EXTENDED RELEASE / ORAL2013-12-265bbf6a4d5a75…
2024-11-08 22:44 UTC · 3 captures of this ZIP2024-11A202886-001POTASSIUM CHLORIDE8MEQCAPSULE, EXTENDED RELEASE / ORAL2013-12-26d8e5a09893c0…
2024-11-08 22:44 UTC · 3 captures of this ZIP2024-11A202886-002POTASSIUM CHLORIDE10MEQCAPSULE, EXTENDED RELEASE / ORAL2013-12-26d8e5a09893c0…
2024-10-29 15:01 UTC2024-10A202886-001POTASSIUM CHLORIDE8MEQCAPSULE, EXTENDED RELEASE / ORAL2013-12-26d06236e962d9…
2024-10-29 15:01 UTC2024-10A202886-002POTASSIUM CHLORIDE10MEQCAPSULE, EXTENDED RELEASE / ORAL2013-12-26d06236e962d9…
2024-08-13 05:28 UTC · 3 captures of this ZIP2024-08A202886-001POTASSIUM CHLORIDE8MEQCAPSULE, EXTENDED RELEASE / ORAL2013-12-2679d66fd596c7…
2024-08-13 05:28 UTC · 3 captures of this ZIP2024-08A202886-002POTASSIUM CHLORIDE10MEQCAPSULE, EXTENDED RELEASE / ORAL2013-12-2679d66fd596c7…
2024-07-13 05:37 UTC · 2 captures of this ZIP2024-07A202886-001POTASSIUM CHLORIDE8MEQCAPSULE, EXTENDED RELEASE / ORAL2013-12-26301d65b070ca…
2024-07-13 05:37 UTC · 2 captures of this ZIP2024-07A202886-002POTASSIUM CHLORIDE10MEQCAPSULE, EXTENDED RELEASE / ORAL2013-12-26301d65b070ca…
2024-06-18 03:08 UTC · 5 captures of this ZIP2024-06A202886-001POTASSIUM CHLORIDE8MEQCAPSULE, EXTENDED RELEASE / ORAL2013-12-261e350fbaab3a…
2024-06-18 03:08 UTC · 5 captures of this ZIP2024-06A202886-002POTASSIUM CHLORIDE10MEQCAPSULE, EXTENDED RELEASE / ORAL2013-12-261e350fbaab3a…
2024-05-31 18:47 UTC2024-05A202886-001POTASSIUM CHLORIDE8MEQCAPSULE, EXTENDED RELEASE / ORAL2013-12-268072bd15b7f6…
2024-05-31 18:47 UTC2024-05A202886-002POTASSIUM CHLORIDE10MEQCAPSULE, EXTENDED RELEASE / ORAL2013-12-268072bd15b7f6…
2022-06-29 02:47 UTC · 2 captures of this ZIP2022-06A202886-001POTASSIUM CHLORIDE8MEQCAPSULE, EXTENDED RELEASE / ORALAB2013-12-265c6f7cd8ea54…
2022-06-29 02:47 UTC · 2 captures of this ZIP2022-06A202886-002POTASSIUM CHLORIDE10MEQCAPSULE, EXTENDED RELEASE / ORALAB2013-12-265c6f7cd8ea54…
2022-04-08 23:34 UTC2022-04A202886-001POTASSIUM CHLORIDE8MEQCAPSULE, EXTENDED RELEASE / ORALAB2013-12-265d02ea3f76ae…
2022-04-08 23:34 UTC2022-04A202886-002POTASSIUM CHLORIDE10MEQCAPSULE, EXTENDED RELEASE / ORALAB2013-12-265d02ea3f76ae…

Observed Orange Book normalized TE history#

Normalized TE history page 1 of 2 · 50 observed states.

Captured, Edition, Application-product table
CapturedEditionApplication-productTE codeOrderSource SHA-256
2022-06-29 02:47 UTC · 2 captures of this ZIP2022-06A202886-001AB15c6f7cd8ea54…
2022-06-29 02:47 UTC · 2 captures of this ZIP2022-06A202886-002AB15c6f7cd8ea54…
2022-04-08 23:34 UTC2022-04A202886-001AB15d02ea3f76ae…
2022-04-08 23:34 UTC2022-04A202886-002AB15d02ea3f76ae…
2022-04-04 05:41 UTC2022-04A202886-001AB14b0b4de00fa7…
2022-04-04 05:41 UTC2022-04A202886-002AB14b0b4de00fa7…
2019-12-13 00:20 UTC2019-12A202886-001AB174a2ff9319b5…
2019-12-13 00:20 UTC2019-12A202886-002AB174a2ff9319b5…
2022-03-09 01:35 UTC2022-03A202886-001AB1bb7c543d1eb4…
2022-03-09 01:35 UTC2022-03A202886-002AB1bb7c543d1eb4…
2021-12-28 21:50 UTC2021-12A202886-001AB1782e0a99824c…
2021-12-28 21:50 UTC2021-12A202886-002AB1782e0a99824c…
2021-05-05 16:15 UTC · 3 captures of this ZIP2021-05A202886-001AB187673890dc5c…
2021-05-05 16:15 UTC · 3 captures of this ZIP2021-05A202886-002AB187673890dc5c…
2021-03-12 10:30 UTC2021-03A202886-001AB15aa47cf7b7d7…
2021-03-12 10:30 UTC2021-03A202886-002AB15aa47cf7b7d7…
2020-12-22 03:56 UTC2020-12A202886-001AB18869cabd3fbd…
2020-12-22 03:56 UTC2020-12A202886-002AB18869cabd3fbd…
2020-11-12 02:37 UTC2020-11A202886-001AB1c0c555d07b60…
2020-11-12 02:37 UTC2020-11A202886-002AB1c0c555d07b60…
2019-12-14 00:12 UTC2019-12A202886-001AB13f01610625f2…
2019-12-14 00:12 UTC2019-12A202886-002AB13f01610625f2…
2019-09-15 20:21 UTC2019-09A202886-001AB1b00525d2431f…
2019-09-15 20:21 UTC2019-09A202886-002AB1b00525d2431f…
2019-07-19 19:46 UTC2019-07A202886-001AB1ea99ee380514…
2019-07-19 19:46 UTC2019-07A202886-002AB1ea99ee380514…
2024-02-18 07:12 UTC2024-02A202886-001AB11c564ffb4f44…
2024-02-18 07:12 UTC2024-02A202886-002AB11c564ffb4f44…
2023-12-20 04:57 UTC2023-12A202886-001AB1ea1830bbd6c7…
2023-12-20 04:57 UTC2023-12A202886-002AB1ea1830bbd6c7…
2023-11-28 05:40 UTC · 2 captures of this ZIP2023-11A202886-001AB1a72a2bbeb626…
2023-11-28 05:40 UTC · 2 captures of this ZIP2023-11A202886-002AB1a72a2bbeb626…
2023-10-25 00:34 UTC · 2 captures of this ZIP2023-10A202886-001AB19b2671bbb829…
2023-10-25 00:34 UTC · 2 captures of this ZIP2023-10A202886-002AB19b2671bbb829…
2023-07-15 15:27 UTC · 2 captures of this ZIP2023-07A202886-001AB1a67488948f0b…
2023-07-15 15:27 UTC · 2 captures of this ZIP2023-07A202886-002AB1a67488948f0b…
2023-06-13 01:57 UTC · 3 captures of this ZIP2023-06A202886-001AB13f0d92c62455…
2023-06-13 01:57 UTC · 3 captures of this ZIP2023-06A202886-002AB13f0d92c62455…
2023-05-13 08:27 UTC2023-05A202886-001AB1053a50430f4f…
2023-05-13 08:27 UTC2023-05A202886-002AB1053a50430f4f…

openFDA label cross-check#

OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.

Matched openFDA labels page 1 of 1 · 1 matching rows.

Brand, Generic, Manufacturer table
BrandGenericManufacturerSPL set IDEffective dateAvailable safety fieldsJoin
4f4bc944-e9f3-46bf-919e-0bdd4bb9b34a29760b2d-6394-4911-ae6b-7ba5e9079ded2014-01-09Warnings, Adverse reactionsExact identifier
spl id: 4f4bc944-e9f3-46bf-919e-0bdd4bb9b34a
spl set id: 29760b2d-6394-4911-ae6b-7ba5e9079ded

Reported adverse events (FAERS/openFDA)#

Adverse event summaries are temporarily unavailable. Other product information remains available.